

Financial news for CBAY dated on 2020-05-26: CymaBay Therapeutics shares are trading higher after HC Wainwright upgraded the stock from Neutral to Buy and announced a price target of \$9 per share.

Financial news for CBAY dated on 2020-05-26: HC Wainwright & Co. Upgrades CymaBay Therapeutics to Buy, Announces \$9 Price Target

Financial news for CBAY dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for CBAY dated on 2020-05-13: Benzinga's Top Upgrades, Downgrades For May 13, 2020

Financial news for CBAY dated on 2020-05-13: 10 Biggest Price Target Changes For Wednesday

Financial news for CBAY dated on 2020-05-13: B. Riley FBR Upgrades CymaBay Therapeutics to Buy, Raises Price Target of \$6

Financial news for CBAY dated on 2020-05-13: 84 Biggest Movers From Yesterday

Financial news for CBAY dated on 2020-05-12: Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage Study

Financial news for CBAY dated on 2020-05-12: Mid-Afternoon Market Update: Dow Falls 150 Points; Eventbrite Shares Tumble On Downbeat Q1 Results

Financial news for CBAY dated on 2020-05-12: Mid-Day Market Update: Crude Oil Rises Over 7%; Genfit Shares Plummet

Financial news for CBAY dated on 2020-05-12: 60 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CBAY dated on 2020-05-12: UPDATE: SVB Leerink Upgrades CymaBay Therapeutics To Outperform, Raises Target To \$6 Notes Seladelpar 'findings are a near-best case scenario for CBAY, in our view, and would appear to reopen the door to develop seladelpar in both PBC and NASH'

Financial news for CBAY dated on 2020-05-12: UPDATE: Raymond James Upgrades CymaBay Therapeutics To Outperform, Announces \$7 Target Notes 'Pending FDA agreement to lift the current clinical hold, seladelpar is back. The development is stunning'

Financial news for CBAY dated on 2020-05-12: A Look Into CymaBay Therapeutics Price Over Earnings

Financial news for CBAY dated on 2020-05-12: Benzinga's Top Upgrades, Downgrades For May 12, 2020

Financial news for CBAY dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for CBAY dated on 2020-05-12: 10 Biggest Price Target Changes For Tuesday

Financial news for CBAY dated on 2020-05-12: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CBAY dated on 2020-05-12: Cantor Fitzgerald Reiterates Overweight on CymaBay Therapeutics, Raises Price Target to \$15

Financial news for CBAY dated on 2020-05-12: Stifel Upgrades CymaBay Therapeutics to Buy, Raises Price Target of \$8

Financial news for CBAY dated on 2020-05-12: 32 Stocks Moving in Tuesday's Pre-Market Session

Financial news for CBAY dated on 2020-05-12: CymaBay shares are trading higher after the company announced an independent expert panel unanimously concluded there is no evidence of liver injury in the Phase 2b NASH study of seladelpar. The panel supported re-initiating development of seladelpar.

Financial news for CBAY dated on 2020-05-12: SVB Leerink Upgrades CymaBay Therapeutics to Outperform, Raises Price Target to \$6

Financial news for CBAY dated on 2020-05-12: Evercore ISI Group Upgrades CymaBay Therapeutics to Outperform, Announces \$15 Price Target

Financial news for CBAY dated on 2020-05-12: Raymond James Upgrades CymaBay Therapeutics to Outperform, Announces \$7 Price Target

Financial news for CBAY dated on 2020-05-11: 14 Stocks Moving In Monday's After-Hours Session

Financial news for CBAY dated on 2020-05-11: CymaBay Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.

Financial news for CBAY dated on 2020-05-11: CymaBay Therapeutics Q1 EPS \$(0.190) Beats \$(0.300) Estimate

Financial news for CBAY dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for CBAY dated on 2020-03-20: Citigroup Maintains Buy on CymaBay Therapeutics, Lowers Price Target to \$1.6

Financial news for CBAY dated on 2020-03-18: B. Riley FBR Maintains Neutral on CymaBay Therapeutics, Lowers Price Target to \$1.5

Financial news for CBAY dated on 2020-03-13: Benzinga's Top Upgrades, Downgrades For March 13, 2020

Financial news for CBAY dated on 2020-03-13: Cantor Fitzgerald Upgrades CymaBay Therapeutics to Overweight, Raises Price Target to \$5

Financial news for CBAY dated on 2020-03-12: CymaBay Therapeutics Q4 EPS \$(0.43) Misses \$(0.39) Estimate

Financial news for CBAY dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for CBAY dated on 2020-01-02: Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In

Financial news for CBAY dated on 2019-12-20: 28 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for CBAY dated on 2019-12-20: 21 Stocks Moving in Friday's Pre-Market Session

Financial news for CBAY dated on 2019-12-19: CymaBay Therapeutics To Reduce Workforce By 60%, Explore Strategic Opportunities With Regard To Its Development

Financial news for CBAY dated on 2019-12-13: Newtyn Management Reports 5.4% Passive Stake In CymaBay Therapeutics

Financial news for CBAY dated on 2019-12-13: CymaBay Therapeutics shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock is trading on above-average volume.

Financial news for CBAY dated on 2019-11-26: UPDATE: Raymond James Downgrades CymaBay Therapeutics To Market Perform 'given the unexpected setback for seladelpar (all programs terminated or halted on Monday 11/25) and uncertainty around any path forward for the lead PBC program'

Financial news for CBAY dated on 2019-11-26: Roth Capital Downgrades CymaBay Therapeutics to Neutral, Lowers Price Target to \$2

Financial news for CBAY dated on 2019-11-26: Benzinga's Top Upgrades, Downgrades For November 26, 2019

Financial news for CBAY dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for CBAY dated on 2019-11-26: Cantor Fitzgerald Downgrades CymaBay Therapeutics to Neutral

Financial news for CBAY dated on 2019-11-26: 45 Biggest Movers From Yesterday

Financial news for CBAY dated on 2019-11-26: Raymond James Downgrades CymaBay Therapeutics to Market Perform

Financial news for CBAY dated on 2019-11-25: Mid-Afternoon Market Update: Dow Rises 150 Points; Sorrento Therapeutics Shares Spike Higher

Financial news for CBAY dated on 2019-11-25: Oppenheimer Downgrades CymaBay Therapeutics to Perform

Financial news for CBAY dated on 2019-11-25: CymaBay Halts Study On Lead Clinical Program, Stock Crashes

Financial news for CBAY dated on 2019-11-25: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for CBAY dated on 2019-11-25: Mid-Day Market Update: Medicines Company Jumps Following Acquisition News; CymaBay Therapeutics Shares Plunge

Financial news for CBAY dated on 2019-11-25: Stocks That Hit 52-Week Lows On Monday

Financial news for CBAY dated on 2019-11-25: Evercore ISI Group Downgrades CymaBay Therapeutics to In-Line

Financial news for CBAY dated on 2019-11-25: Mid-Morning Market Update: Markets Open Higher; Schwab, TD Ameritrade Confirm \$26B Merger

Financial news for CBAY dated on 2019-11-25: Stifel Downgrades CymaBay Therapeutics to Hold

Financial news for CBAY dated on 2019-11-25: 36 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for CBAY dated on 2019-11-25: CymaBay Therapeutics shares are trading lower after the company reported a halt in the clinical development of its Seladelpar.

Financial news for CBAY dated on 2019-11-25: CymaBay Therapeutics Reports Halt In Clinical Development Of Seladelpar

Financial news for CBAY dated on 2019-11-07: 60 Biggest Movers From Yesterday

Financial news for CBAY dated on 2019-11-06: 62 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CBAY dated on 2019-11-05: CymaBay Therapeutics Q3 EPS \$(0.38) Misses \$(0.37) Estimate

Financial news for CBAY dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for CBAY dated on 2019-11-04: CymaBay Therapeutics Reaches Target Enrollment In ENHANCE Global Phase 3 Study Evaluating Seladelpar For Primary Biliary Cholangitis

Financial news for CBAY dated on 2019-10-11: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

Financial news for CBAY dated on 2019-10-10: Stocks That Hit 52-Week Lows On Thursday

Financial news for CBAY dated on 2019-10-10: The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

Financial news for CBAY dated on 2019-10-09: Stocks That Hit 52-Week Lows On Wednesday

Financial news for CBAY dated on 2019-10-09: The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug

Financial news for CBAY dated on 2019-09-18: The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

Financial news for CBAY dated on 2019-08-08: CymaBay Therapeutics Option Alert: Jan 17 \$7.5 Calls Sweep (2) near the Ask: 2648 @ \$0.676 vs 875 OI; Ref=\$5.55

Financial news for CBAY dated on 2019-08-07: CymaBay Therapeutics Q2 EPS \$(0.35) Beats \$(0.37) Estimate

Financial news for CBAY dated on 2019-06-25: The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

Financial news for CBAY dated on 2019-06-25: Stifel Nicolaus Initiates Coverage On CymaBay Therapeutics with Buy Rating, Announces \$14 Price Target

Financial news for CBAY dated on 2019-06-18: CymaBay Therapeutics Announces IND To Commence Clinical Study Of Seladelpar To Treat Primary Sclerosing Cholangitis

Financial news for CBAY dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for CBAY dated on 2019-06-12: A Look At Benzinga Pro's Most-Searched Tickers For June 12

Financial news for CBAY dated on 2019-06-12: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., Jun. 12, 2019

Financial news for CBAY dated on 2019-06-12: UPDATE: Raymond James Upgrades CymaBay Therapeutics To Strong Buy As Firm Notes '1) NASH is now a "free call option", 2) PBC provides "valuation floor," 3) market reaction to surrogate endpoint data is "overblown"'

Financial news for CBAY dated on 2019-06-12: Benzinga's Top Upgrades, Downgrades For June 12, 2019

Financial news for CBAY dated on 2019-06-12: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CBAY dated on 2019-06-12: The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

Financial news for CBAY dated on 2019-06-12: Raymond James Upgrades CymaBay Therapeutics to Strong Buy

Financial news for CBAY dated on 2019-06-12: 66 Biggest Movers From Yesterday

Financial news for CBAY dated on 2019-06-11: CymaBay Therapeutics Shares Slightly Higher After Hours As Hearing Raymond James Upgraded To Strong Buy, Set \$19 Price Target

Financial news for CBAY dated on 2019-06-11: Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Casey's General Stores Shares Surge On Earnings Beat

Financial news for CBAY dated on 2019-06-11: 48 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CBAY dated on 2019-06-11: Mid-Day Market Update: Chico's FAS Rises On Upbeat Earnings; CymaBay Therapeutics Shares Plummet

Financial news for CBAY dated on 2019-06-11: Mid-Morning Market Update: Markets Open Higher; H & R Block Earnings Top Expectations

Financial news for CBAY dated on 2019-06-11: CymaBay Therapeutics shares are trading lower after the company reported data from its Phase 2b study of Seladelpar in patients with nonalcoholic steatohepatitis. Data showed reductions in liver fat were minimal and not significant compared to the placebo.

Financial news for CBAY dated on 2019-06-11: Viking Therapeutics Shares Up 5.7% Following Concerning Data From A Phase 2b Study Of Seladelpar In Patients With Nonalcoholic Steatohepatitis By CymaBay Therapeutics

Financial news for CBAY dated on 2019-06-11: CymaBay Therapeutics Plummets 40% Following Liver Disease Data

Financial news for CBAY dated on 2019-06-11: 31 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CBAY dated on 2019-06-11: CymaBay Therapeutics Reports Data From Phase 2b Study Of Seladelpar In Patients With Nonalcoholic Steatohepatitis; Reductions In Liver Fat Were Minimal, Not Significant Compared To Placebo, Reductions In Markers Of Liver Injury Were Clinically Meaningful

Financial news for CBAY dated on 2019-06-07: CymaBay Therapeutics Option Alert: Jul 19 \$17.5 Calls at the Ask: 500 @ \$0.7 vs 50 OI; Ref=\$11.4

Financial news for CBAY dated on 2019-06-07: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for CBAY dated on 2019-05-20: CymaBay Highlights Presentation Of Data At Digestive Disease Week On Results From Seladelpar Program For Treatment Of Primary

Biliary Diseases

Financial news for CBAY dated on 2019-05-18: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for CBAY dated on 2019-05-14: Citigroup Initiates Coverage On CymaBay Therapeutics Inc. - Common Stock with Buy Rating, Announces \$21 Price Target

Financial news for CBAY dated on 2019-05-08: CymaBay Therapeutics Inc. - Common Stock Q1 EPS \$(0.37) Misses \$(0.34) Estimate

Financial news for CBAY dated on 2019-05-08: CymaBay Therapeutics Inc. Q1 EPS \$(0.37) Misses \$(0.34) Estimate

Financial news for CBAY dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for CBAY dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for CBAY dated on 2019-04-02: 32 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CBAY dated on 2019-03-06: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CBAY dated on 2019-03-06: The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

Financial news for CBAY dated on 2019-03-06: 10 Stocks To Watch For March 6, 2019

Financial news for CBAY dated on 2019-03-05: 5 Stocks Moving In Tuesday's After-Hours Session

Financial news for CBAY dated on 2019-03-05: CymaBay Reports Offering Of Common Stock, No Size Disclosed

Financial news for CBAY dated on 2019-02-28: CymaBay Therapeutics Inc. Q4 EPS \$(0.32) Beats \$(0.36) Estimate

Financial news for CBAY dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for CBAY dated on 2019-02-19: 54 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CBAY dated on 2019-02-19: CymaBay Therapeutics shares are trading higher after the company announced early enrollment of its Phase 2b study of Seladelpar in patients with non-alcoholic steatohepatitis.

Financial news for CBAY dated on 2019-02-19: CymaBay Therapeutics Announces Early Enrollment Of Phase 2b Study Of Seladelpar In Patients With Nonalcoholic Steatohepatitis

Financial news for CBAY dated on 2019-02-15: CymaBay shares are trading higher after the company's Seladelpar was granted breakthrough therapy designation by the FDA for the treatment of Primary Biliary Cholangitis.

Financial news for CBAY dated on 2019-02-15: CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation By FDA For The Treatment Of Primary Biliary Cholangitis

Financial news for CBAY dated on 2019-02-14: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for CBAY dated on 2019-02-06: Benzinga's Top Upgrades, Downgrades For February 6, 2019

Financial news for CBAY dated on 2019-02-06: B. Riley FBR Initiates Coverage On CymaBay Therapeutics with Neutral Rating, Announces \$9 Price Target

Financial news for CBAY dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for CBAY dated on 2018-11-14: 13F From Omega Shows Liquidated ~377K Share Stake In Cymabay Therapeutics

Financial news for CBAY dated on 2018-11-14: 55 Biggest Movers From Yesterday

Financial news for CBAY dated on 2018-11-13: 36 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CBAY dated on 2018-11-11: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for CBAY dated on 2018-11-06: CymaBay Therapeutics Inc. Q3 EPS \$(0.34) Down From \$(0.21) YoY

Financial news for CBAY dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for CBAY dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for CBAY dated on 2018-10-30: CymaBay Announces Initiation Of Seladelpar Global Phase 3 Registration Study (ENHANCE) For Treatment Of Primary Biliary Cholangitis And Additional Corporate Updates

Financial news for CBAY dated on 2018-10-03: CymaBay Therapeutics Highlights 2 Abstracts Showing Added Results From Ongoing Phase 2 Study Of Seladelpar In Patients With PBC

Financial news for CBAY dated on 2018-08-09: CymaBay Therapeutics Inc. - Common Stock Q2 EPS \$(0.30) Misses \$(0.25) Estimate

Financial news for CBAY dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for CBAY dated on 2018-06-28: Raymond James Initiates Coverage On CymaBay Therapeutics with Outperform Rating, Announces \$20 Price Target

Financial news for CBAY dated on 2018-06-01: 58 Biggest Movers From Yesterday

Financial news for CBAY dated on 2018-05-31: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for CBAY dated on 2018-05-31: 28 Stocks Moving In Thursday's Pre-Market Session

Financial news for CBAY dated on 2018-05-15: 13F From Cooperman's Omega Shows New 280K Share Stake In Cymabay Therapeutics

Financial news for CBAY dated on 2018-05-08: CymaBay Therapeutics Shares down 10.6% After Hours Following Larger-Than-Expected Q1 Loss

Financial news for CBAY dated on 2018-05-08: CymaBay Therapeutics Inc. - Common Stock Q1 EPS \$(0.32) Misses \$(0.14) Estimate

Financial news for CBAY dated on 2018-05-08: CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis

Financial news for CBAY dated on 2018-04-12: 38 Biggest Movers From Yesterday

Financial news for CBAY dated on 2018-04-11: Benzinga Pro's Most-Searched Tickers For Wed., Apr. 11, 2018

Financial news for CBAY dated on 2018-04-11: 28 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CBAY dated on 2018-04-11: Mid-Day Market Update: Analogic Falls Following Acquisition News; EyeGate Pharmaceuticals Shares Gain

Financial news for CBAY dated on 2018-04-11: CymaBay Therapeutics Up 15% After Co. Earlier Reported Positive Results In Phase 2 Seladelpar Study To Be Presented at EASL Conference This Week

Financial news for CBAY dated on 2018-04-11: Mid-Morning Market Update: Markets Open Lower; Fastenal Posts In-Line Earnings

Financial news for CBAY dated on 2018-04-11: CymaBay Announces 'Positive' New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018

Financial news for CBAY dated on 2018-04-03: 41 Biggest Movers From Yesterday

Financial news for CBAY dated on 2018-03-16: Cymabay Therapeutics Shares Up 11.4% After Co. Wednesday Reported Better-Than-Expected Q4 Loss And Strong Sales Beat

Financial news for CBAY dated on 2018-03-15: Cymabay Therapeutics Reports Q4 EPS \$(0.11) vs \$(0.19) Est., Sales \$5.2M vs \$1.25M Est.

Financial news for CBAY dated on 2018-02-13: Evercore ISI Group Initiates Coverage On CymaBay Therapeutics with Outperform Rating

Financial news for CBAY dated on 2018-02-13: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CBAY dated on 2018-01-30: CymaBay Prices Offering Of 11.6M Shares At \$10.80/Share

Financial news for CBAY dated on 2018-01-29: CymaBay Files For Shelf Offering, No Size Disclosed

Financial news for CBAY dated on 2018-01-11: JP Morgan Healthcare Conference Concludes Today, Presenters Include: CymaBay, Orthofix, Analogic, Achaogen, Immunomedics, and Dynavax

Financial news for CBAY dated on 2018-01-08: CymaBay Earlier Announced Enrollment Has Begun In Long-Term Extension Study Of Seladelpar

Financial news for CBAY dated on 2018-01-08: CymaBay Therapeutics Reports Received \$5M Milestone Payment For Arhalofenate From Kowa Pharma America

Financial news for CBAY dated on 2017-12-22: The Companies That Led 2017's Biotech Rally

Financial news for CBAY dated on 2017-11-30: Oppenheimer's Top Stock Picks For December

Financial news for CBAY dated on 2017-11-08: Cymabay Therapeutics Reports Q3 EPS \$(0.21) vs \$(0.19) Est.

Financial news for CBAY dated on 2017-10-31: CymaBay Therapeutics Names Sujal Shah Pres, CEO

Financial news for CBAY dated on 2017-10-16: 29 Top Stock Ideas For October And Beyond

Financial news for CBAY dated on 2017-10-09: CymaBay Reports Presentation Of Interim Results From Ongoing Phase 2 Study Of Patients With Primary Biliary Cholangitis: Showed 'potential for superior efficacy and better tolerability over existing second-line therapy'

Financial news for CBAY dated on 2017-09-20: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for CBAY dated on 2017-09-20: Benzinga's Top Upgrades, Downgrades For September 20, 2017

Financial news for CBAY dated on 2017-09-20: Cantor Fitzgerald Initiates Coverage On CymaBay Therapeutics with Overweight Rating, Announces \$16.00 Price Target

Financial news for CBAY dated on 2017-09-11: CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for Treatment of Primary Biliary Cholangitis

Financial news for CBAY dated on 2017-08-23: Benzinga's Top Upgrades, Downgrades For August 23, 2017

Financial news for CBAY dated on 2017-08-23: Leerink Swann Initiates Coverage On CymaBay Therapeutics with Outperform Rating, Announces \$12.00 Price Target

Financial news for CBAY dated on 2017-08-15: CymaBay Therapeutics Reports Publication Of Seladelpar Proof-Of-Concept Study For Primary Biliary Cholangitis In Lancet Gastroenterology, Hepatology

Financial news for CBAY dated on 2017-08-10: CymaBay Reports Q2 EPS \$(0.31) vs \$(0.26) Est.

Financial news for CBAY dated on 2017-07-20: 5 Biggest Price Target Changes For Thursday

Financial news for CBAY dated on 2017-07-19: CymaBay Therapeutics Prices 13M Share Common Stock Offering At \$6.50/Share

Financial news for CBAY dated on 2017-07-18: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CBAY dated on 2017-07-17: CymaBay Reports 10M Share Common Stock Offering

Financial news for CBAY dated on 2017-07-17: 18 Biggest Mid-Day Gainers For Monday

Financial news for CBAY dated on 2017-07-17: Mid-Day Market Update: Sevcon Surges Following Acquisition News; TherapeuticsMD Shares Slide

Financial news for CBAY dated on 2017-07-17: Mid-Morning Market Update: Markets Edge Higher; BlackRock Profit Misses Views

Financial news for CBAY dated on 2017-07-17: CymaBay Announces 'Positive' Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

Financial news for CBAY dated on 2017-06-23: Oppenheimer Initiates Coverage On CymaBay Therapeutics with Outperform Rating, Announces \$8.00 Price Target

Financial news for CBAY dated on 2017-05-11: CymaBay Reports Q1 EPS \$(0.20) vs \$(0.27) Est., Sales \$4.793M

Financial news for CBAY dated on 2017-04-03: H.C. Wainwright Holding NASH Investor Conference Today; Attendees Include Allergan, Enanta Pharma, Madrigal Pharma, Vascular Biogenics, Albireo Pharma, CymaBay, Gemphire Therapeutics, And Galectin Therapeutics

Financial news for CBAY dated on 2017-03-29: CymaBay Reports Pres, CEO, Harold Van Wart, to Retire; Board Has Promoted Sujal Shah as Interim Pres, CEO

Financial news for CBAY dated on 2017-03-24: 15 Biggest Mid-Day Gainers For Friday

Financial news for CBAY dated on 2017-03-24: 16 Stocks Moving In Friday's Pre-Market Session

Financial news for CBAY dated on 2017-03-23: Cymabay Therapeutics Reports Q4 EPS \$(0.30) vs \$(0.28) Est.

Financial news for CBAY dated on 2017-02-02: 18 Biggest Mid-Day Losers For Thursday

Financial news for CBAY dated on 2017-02-02: CymaBay Prices 5.18M Share Offering At \$1.93/Share

Financial news for CBAY dated on 2017-02-02: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for CBAY dated on 2017-02-01: CymaBay Reports Proposed Public Offering of Common Stock, Terms Not Disclosed

Financial news for CBAY dated on 2017-01-30: 15 Biggest Mid-Day Gainers For Monday

Financial news for CBAY dated on 2017-01-30: Mid-Day Market Update: Dow Falls Over 150 Points; Calithera Biosciences Shares Spike Higher

Financial news for CBAY dated on 2017-01-30: 7 Biggest Price Target Changes For Monday

Financial news for CBAY dated on 2017-01-30: H.C. Wainwright Upgrades CymaBay Therapeutics To Buy, Raises Price Target To \$6

Financial news for CBAY dated on 2017-01-05: CymaBay Therapeutics Reports Co. Reached Agreement With EMA On All Key Elements of Planned 3 Program, Similar To Agreed Upon Deal Of FDA

Financial news for CBAY dated on 2017-01-04: Mid-Afternoon Market Update: NASDAQ Gains Over 50 Points; Evoke Pharma Shares Spike Higher

Financial news for CBAY dated on 2017-01-04: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for CBAY dated on 2017-01-04: Mid-Day Market Update: Crude Oil Up Over 1%; Agile Therapeutics Shares Slide

Financial news for CBAY dated on 2017-01-04: Mid-Morning Market Update: Markets Open Higher; UniFirst Posts Lower Q1 Profit

Financial news for CBAY dated on 2017-01-04: 15 Stocks Moving In Wednesday's Pre-

Market Session

Financial news for CBAY dated on 2017-01-03: CymaBay Shares Resume Trade, Now Up 56%

Financial news for CBAY dated on 2017-01-03: CymaBay Therapeutics Shares to Resume Trade at 4:30 p.m. EST

Financial news for CBAY dated on 2017-01-03: UPDATE: Kowa Pharma Announces Licensing Deal with CymaBay for Exclusive US Rights to Arhalofenate

Financial news for CBAY dated on 2017-01-03: CymaBay Therapeutics Reports Deal with Kowa Pharma America to License Gout Compound

Financial news for CBAY dated on 2016-12-07: CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

Financial news for CBAY dated on 2016-11-10: CymaBay Reports US Orphan Drug Designation for MBX-8025 for Treatment of Primary Biliary Cholangitis

Financial news for CBAY dated on 2016-11-09: CymaBay Reports Q3 EPS \$(0.25) vs \$(0.29) Est.

Financial news for CBAY dated on 2016-11-09: CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis

Financial news for CBAY dated on 2016-10-20: CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting

Financial news for CBAY dated on 2016-10-20: CymaBay Release Confirms MBX-8025 Received EMA PRiority MEdicines (PRIME) Designation for Treatment of Primary Biliary Cholangitis

Financial news for CBAY dated on 2016-10-19: European Medicines Agency Issues Release Highlighting Recommendations on Eligibility to PRIME Scheme, Includes Cymabay's MBX-8025 Listed as 'Eligibility Granted'

Financial news for CBAY dated on 2016-10-11: CymaBay Reports Newly-Issued US Patent for MBX-8025 for Treatment of NAFLD, NASH

Financial news for CBAY dated on 2016-10-05: CymaBay Therapeutics Reports Plans to Initiate Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis

Financial news for CBAY dated on 2016-08-09: CymaBay Reports Q2 Loss/Share (\$0.30) vs Est Loss/Share (\$0.32)

Financial news for CBAY dated on 2016-06-01: Mid-Afternoon Market Update: Daktronics Drops Following Downbeat Results; Galena Biopharma Shares Spike Higher

Financial news for CBAY dated on 2016-06-01: H.C. Wainwright Downgrades CymaBay Therapeutics to Neutral, Lowers PT to \$2.25

Financial news for CBAY dated on 2016-05-31: Today's Top 10 Pre-Market Gainers

Financial news for CBAY dated on 2016-05-31: CymaBay Reports It Has Discontinued Current Phase 2 Study Of MBX-8025, After Determining Study Met Objective Establishing Proof Of Concept With Marked Improvement In Biochemical Markers Of Cholestasis

Financial news for CBAY dated on 2016-05-11: Cymabay Therapeutics Reports Q1 EPS \$(0.29) Vs Est \$(0.28)

Financial news for CBAY dated on 2016-04-06: CFO Shah Buys 55,000 Shares of Cymabay Therapeutics @\$1.39/Share -Form 4

Financial news for CBAY dated on 2016-03-30: H.C. Wainwright Maintains Buy on CymaBay Therapeutics, Lowers PT to \$6.00

Financial news for CBAY dated on 2016-03-29: CymaBay Reports Q4 Loss of \$6M vs \$12.7M Loss in Same Qtr. Last Year

Financial news for CBAY dated on 2016-03-29: Earnings Scheduled For March 29, 2016

Financial news for CBAY dated on 2016-03-28: CymaBay Announces Paul Truex & Robert Weiland To Board of Directors

Financial news for CBAY dated on 2016-03-28: CymaBay Therapeutics Reports Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology

Financial news for CBAY dated on 2016-03-18: Mid-Morning Market Update: Markets Open Higher; Tiffany Q4 Profit Beats Views

Financial news for CBAY dated on 2016-03-17: CymaBay Therapeutics to Resume Trading at 4:30 PM ET

Financial news for CBAY dated on 2016-03-17: UPDATE: CymaBay Offers Results from Pilot Phase 2 Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia

Financial news for CBAY dated on 2016-03-17: CymaBay Offers Results from Pilot Phase 2 Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia: Showed Meaningful Reduction in LDL-C for Subset of Patients

Financial news for CBAY dated on 2016-03-17: CymaBay Therapeutics Shares Halted News Pending

Financial news for CBAY dated on 2016-01-20: CymaBay Reports Successful Closing of End of Phase 2 Discussions with FDA Related to Arhalofenate

Financial news for CBAY dated on 2015-12-01: 15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare Conference

Financial news for CBAY dated on 2015-11-12: Cymabay Therapeutics Reports Q3 EPS \$(0.27) vs \$(0.33) Est.

Financial news for CBAY dated on 2015-11-10: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis

Financial news for CBAY dated on 2015-11-05: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology (ACR) Annual Meeting, November 6 - 11

Financial news for CBAY dated on 2015-11-02: Stocks Hitting 52-Week Lows

Financial news for CBAY dated on 2015-09-08: Time To Buy Micro-Cap CymaBay Therapeutics: H.C. Wainwright

Financial news for CBAY dated on 2015-09-08: Benzinga's Top Initiations

Financial news for CBAY dated on 2015-09-08: H.C. Wainwright Initiates Coverage on CymaBay Therapeutics at Buy, Announces \$12.00 PT

Financial news for CBAY dated on 2015-07-21: Piper Jaffray Starts CymaBay At Overweight With \$4 Target, Discusses MBX-8025

Financial news for CBAY dated on 2015-07-21: Piper Jaffray Initiates Coverage on CymaBay Therapeutics at Overweight, Announces \$4.00 PT

Financial news for CBAY dated on 2015-07-15: Morning Market Gainers

Financial news for CBAY dated on 2015-07-15: CymaBay Prices 7.12M Shares at \$2.81/Share

Financial news for CBAY dated on 2015-07-14: Cymabay Reports Proposed Offering Of Stock

Financial news for CBAY dated on 2015-04-22: CymaBay Reports Orphan Drug Designation for MBX-8025 for Sever Hypertriglyceridemia

Financial news for CBAY dated on 2015-03-25: CymaBay Therapeutics Granted U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia

Financial news for CBAY dated on 2015-03-18: CymaBay Reports Q4 EPS \$(0.87) vs. Est. \$(0.47)

Financial news for CBAY dated on 2015-01-28: CymaBay Announces Preclinical Data Demonstrating Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia

Financial news for CBAY dated on 2015-01-23: Adage Capital Partners Reports 6.80% Passive Stake in Cymabay Therapeutics as of January 14

Financial news for CBAY dated on 2015-01-20: Stifel Raises Price Target On CymaBay Therapeutics

Financial news for CBAY dated on 2015-01-20: 5 Healthcare Stocks With The Highest EPS

Financial news for CBAY dated on 2015-01-12: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate

Financial news for CBAY dated on 2014-09-30: Morning Market Losers

Financial news for CBAY dated on 2014-09-29: CymaBay Therapeutics Completes Enrollment In Arhalofenate Phase 2b Study

Financial news for CBAY dated on 2014-09-19: Roth Capital Initiates Coverage on CymaBay at Buy, Announces \$14.00 PT

Financial news for CBAY dated on 2014-09-17: Cymabay Therapeutics CFO Shah Buys 10,000 Shares @\$7.44/Share -Form 4

Financial news for CBAY dated on 2014-09-17: Stifel Nicolaus Initiates Coverage on CymaBay at Buy, Announces \$10.00 PT

Financial news for CBAY dated on 2014-07-22: Morning Market Losers

Financial news for CBAY dated on 2014-07-17: CymaBay Therapeutics Commences 3.5M Share Offering

Financial news for CBAY dated on 2014-07-09: CymaBay Therapeutics Spokesperson Says No News to Account for Extreme Volatility in Share Price Today

Financial news for CBAY dated on 2014-07-09: CymaBay Therapeutics Shares Resume Trading Following Second Circuit-Breaker Halt; Now Up 53%